ICIs联合治疗应用于EGFR突变靶向治疗耐药后非小细胞肺癌的研究进展

With the development of precision medicine for lung cancer, targeted therapy has greatly improved the survival and prognosis of patients with advanced non-small cell lung cancer (NSCLC), but the occurrence of acquired drug resistance ultimately leads to patients with no targeted drugs available and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiamo, LI, Xingyu, YAO, Longjue, QIU, Ru, ZHANG, Gang, WANG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273152/
https://www.ncbi.nlm.nih.gov/pubmed/37316449
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273152/
https://www.ncbi.nlm.nih.gov/pubmed/37316449
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.17

Ejemplares similares